Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...
Investing.com on MSN8d
Genmab stock surges on strong profit beatInvesting.com -- Shares of Genmab (NASDAQ:GMAB) climbed 7% following the announcement of its fourth-quarter earnings, which revealed a net profit significantly surpassing consensus estimates. The ...
Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Genmab A/S in a report issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the ...
Leerink Partnrs upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a hold rating to a strong-buy rating in a ...
Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...
Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target ...
Insider Monkey on MSN7d
Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing TodayGenmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results